Please login to the form below

Not currently logged in
Email:
Password:

Chronic Myelogenous Leukaemia

This page shows the latest Chronic Myelogenous Leukaemia news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s leukaemia drug Mylotarg backed for use in EU

Pfizer’s leukaemia drug Mylotarg backed for use in EU

The FDA approved the drug last September. “There is an urgent need to improve outcomes for leukaemia patients in Europe,” said Pfizer’s chief development officer Mace Rothenberg. ... Kineret (anakinra) in rare inflammatory condition Still’s

Latest news

  • Novartis pulls EMA application for expanded Tasigna use Novartis pulls EMA application for expanded Tasigna use

    The company said it no longer wishes to seek approval for its cancer treatment Tasigna (nilotinib) in patients with Philadelphia-chromosome-positive chronic myelogenous leukaemia (CML) who did not achieve 'complete ... Tasigna is already approved in the

  • Novartis' Tasigna tops Glivec in long-term trial Novartis' Tasigna tops Glivec in long-term trial

    Boost ahead of patent expiry for leukaemia drug. New phase III data has revealed that Novartis' chronic myelogenous leukaemia (CML) treatment Tasigna is more effective than forerunner Glivec over the

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    The Scottish agency concurred with earlier NICE guidance however and did not support the use of Pfizer's Bosulif (bosutinib) as a back-up treatment for chronic phase, accelerated phase, and ... blast phase Philadelphia chromosome-positive chronic

  • Roche wins conditional EU approval for cancer drug Erivedge Roche wins conditional EU approval for cancer drug Erivedge

    Other drugs to receive conditional approval in Europe in recent years include GlaxoSmithKline's (GSK) renal cell carcinoma treatment Votrient (pazopanib), Pfizer's chronic myelogenous leukaemia (CML) treatment Bosulif (bosutinib) and

  • Pfizer gets CHMP backing for leukaemia drug bosutinib Pfizer gets CHMP backing for leukaemia drug bosutinib

    Provides option for patients resistant to tyrosine kinase inhibitors. Pfizer moved a step closer to getting EU a green light for its chronic myelogenous leukaemia (CML) drug bosutinib last week after ... The CHMP, which is part of the European Medicines

More from news
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    This month Therapy Watch expands its portfolio with the launch of several new trackers across numerous therapy areas including the launch of a new Chronic Myelogenous Leukaemia (CML) study in the ... Therapy Watch CML is part of a wider oncology

  • Research Partnership

    Prescription medicines. Within prescription medicines, we have therapeutic specialists and experience in a broad range of therapy areas from chronic illnesses to rare diseases. ... new Chronic Myelogenous Leukaemia (CML) study in the US.

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics